Roivant Sciences (ROIV) Retained Earnings (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Retained Earnings came in at -$501.8 million in Q1 2026, down 111.0% YoY from $4.6 billion in Q1 2025, and down 110.15% on a QoQ basis from $4.9 billion in Q4 2025.
Roivant Sciences (ROIV) Retained Earnings (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Retained Earnings data on file, last reported at -$501.8 million in Q1 2026.
- Quarterly Retained Earnings fell 111.0% year-over-year to -$501.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$501.8 million (down 111.0% YoY) and the FY2026 annual result came in at -$501.8 million, down 111.0% from the prior year.
- Retained Earnings slipped to -$501.8 million in Q1 2026, from $4.9 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $5.4 billion in Q4 2023 to a low of -$4.4 billion in Q3 2023.
- A 5-year average of $615.6 million and a median of $17.1 million in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 305894.05% — and 2025, when it plunged 208.48%.
- Tracing ROIV's Retained Earnings over 5 years: stood at -$3.7 billion in 2022, then jumped by 245.68% to $5.4 billion in 2023, then fell by 12.42% to $4.7 billion in 2024, then advanced by 4.72% to $4.9 billion in 2025, then sank by 110.15% to -$501.8 million in 2026.
- The last three Retained Earnings figures came in at -$501.8 million (Q1 2026), $4.9 billion (Q4 2025), and -$429.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.13 Bn |
| Mar 31, 2026 | -501.81 Mn |
| Dec 31, 2025 | 4.94 Bn |
| Sep 30, 2025 | -429.11 Mn |
| Jun 30, 2025 | 17.14 Mn |
| Mar 31, 2025 | 4.56 Bn |
| Dec 31, 2024 | 4.72 Bn |
| Sep 30, 2024 | 395.58 Mn |
| Jun 30, 2024 | 671.50 Mn |
| Mar 31, 2024 | -4.08 Mn |
| Dec 31, 2023 | 5.39 Bn |
| Sep 30, 2023 | -4.37 Bn |
| Jun 30, 2023 | -4.10 Bn |
| Mar 31, 2023 | 4.93 Bn |
| Dec 31, 2022 | -3.70 Bn |
| Sep 30, 2022 | -3.39 Bn |
| Jun 30, 2022 | -3.10 Bn |
| Mar 31, 2022 | 4.42 Bn |
| Dec 31, 2021 | 4.36 Bn |
| Sep 30, 2021 | 4.25 Bn |